Summary & Overview
HCPCS C9450: Fluocinolone Acetonide Intravitreal Implant, 0.01 mg
HCPCS Level II code C9450 denotes injection of a fluocinolone acetonide intravitreal implant, 0.01 mg — a sustained-release corticosteroid device used in the eye. Nationally, this code captures a specialized ophthalmic procedure that addresses chronic intraocular inflammation and certain retinal conditions where long-term steroid delivery is clinically indicated. Accurate coding of this implant is important for facility and professional billing, utilization tracking, and payer coverage determinations given the high cost and specialized administration.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for use of the implant, typical sites of service, and what to expect in terms of coding and billing considerations. The publication outlines common benchmarks and policy-relevant issues affecting coverage and reimbursement for intravitreal implant procedures, and it summarizes differences in payer approaches where available.
This summary provides a concise reference for billing managers, compliance officers, and clinical leaders seeking a national perspective on how HCPCS Level II code C9450 is used, documented, and reviewed by major payers.
Billing Code Overview
HCPCS Level II code C9450 represents an injection of a fluocinolone acetonide intravitreal implant, 0.01 mg. This service involves placement of a slow-release corticosteroid implant directly into the vitreous cavity of the eye to treat chronic ocular inflammatory conditions and certain retinal diseases that benefit from sustained intraocular steroid delivery.
-
Service type: Intravitreal implant injection
-
Typical site of service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient setting where intravitreal procedures and ocular implants are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old with chronic noninfectious uveitis or diabetic macular edema refractory to prior therapies presenting to a retinal specialty clinic for intravitreal therapy. The clinician evaluates vision, intraocular pressure, and performs a slit-lamp and dilated fundus exam. After informed discussion and documented consent, topical anesthesia and antisepsis are applied in a procedure room or minor procedure suite. The clinician places the C9450 fluocinolone acetonide intravitreal implant (0.01 mg) through a small-gauge injector into the vitreous cavity under sterile technique. Post-procedure, the patient is monitored for immediate complications (e.g., elevated intraocular pressure, endophthalmitis), receives topical antibiotic and steroid as indicated, and receives instructions for urgent return precautions and scheduled follow-up visits for intraocular pressure checks and implant efficacy monitoring. Typical site of service is an ophthalmology clinic procedure room, ambulatory surgical center, or outpatient hospital department. The service type is an intravitreal implant injection (long-acting corticosteroid implant) performed by a retinal specialist (vitreoretinal surgeon or uveitis-trained ophthalmologist).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician's professional component separate from facility charge (rare for intravitreal implant supply codes). |